Compounded and FDA-approved GLP-1 medications are not the same regulatory category. Here is what that means for consumers.
FDA-approved products
FDA-approved drugs undergo agency review before marketing for safety, effectiveness and quality for their approved indications.
Compounded drugs
FDA states that compounded drugs are not FDA-approved. They can be prepared under specific federal and state conditions for individual patients, but they do not undergo the same premarket review.
Why the distinction matters
Marketing that implies an unapproved compounded drug is the same as an FDA-approved brand can mislead consumers. FDA increased enforcement against this type of promotion in 2026.
Questions to ask
- What exact product would be prescribed?
- Who compounds or dispenses it?
- Why is a compounded preparation being considered?
- What alternatives are available?
- What monitoring will I receive?
Sources & verification
We use primary sources for time-sensitive commercial and regulatory claims.
- FDA — Compounding and the FDA: Questions and Answers
- FDA — Concerns with unapproved GLP-1 drugs used for weight loss
- FDA — Proposed exclusion of semaglutide, tirzepatide and liraglutide from 503B bulks list
Last reviewed: August 19, 2026